New genetic testing facility coming to Scottsdale

Tesis Labs, a Phoenix-based biotech company that provides genetic sequencing to healthcare providers, has announced plans to expand to Scottsdale. 

The new Scottsdale lab will expand the company’s presence in the Valley as Tesis headquarters are located in Phoenix. The company has three other testing labs in Denver, Lafayette, Colo. and Houston. 

The Scottsdale facility will support next-generation sequencing testing for the western U.S. and will provide the additional capacity to handle expanding collaborations with large medical companies, research organizations, medical device companies and large medical organizations.

The lab will also focus on “high-complexity molecular and next-generation sequencing testing to detect chronic and hereditary conditions,” according to the company’s press release. The Tesis technology is designed to detect a variety of conditions, including cancer, heart disease, lung disease, diabetes and Alzheimers. The lab will also offer Infectious Disease testing for diseases like COVID-19, respiratory pathology, wound and other molecular testing. 

Governor Doug Ducey notes the significance of this development in the recent press release, saying that it’s “a positive reflection on Arizona’s high-quality healthcare and bio-tech company.”

The company claims that Tesis has “revolutionized targeted genetic sequencing.” The goal is to provide physicians, hospitals and researchers with the ability to help patients easily and efficiently treat — and eventually overcome — some of the most major chronic conditions. Tesis also wants to help medical device companies and pharmaceuticals to bring new products to market. 

“Genetics and hereditary markers are playing an increasing role in preventive medicine. With earlier identification of disease markers, physicians, patients and families can make more informed prevention and treatment decisions,” says Ron King, Tesis Labs CEO. 

The Scottsdale facility is set to open November 2021.